{"id":8457,"date":"2025-12-12T09:56:24","date_gmt":"2025-12-12T14:56:24","guid":{"rendered":"https:\/\/www.curingheartdisease.com\/?p=8457"},"modified":"2026-07-16T10:59:52","modified_gmt":"2026-07-16T14:59:52","slug":"integratieve-dynamica-van-apolipoproteine-b-lipoproteine-en-c-reactief-proteine-bij-atherosclerotische-progressie","status":"publish","type":"post","link":"https:\/\/www.curingheartdisease.com\/nl\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/","title":{"rendered":"Integratieve dynamiek van apolipoprote\u00efne B, lipoprote\u00efne(a) en C-reactief prote\u00efne bij atherosclerotische progressie"},"content":{"rendered":"

How we think about cardiovascular risk has changed a lot. We used to focus on total cholesterol and later LDL cholesterol (LDL-C) as the main villains. Now, the picture is more precise: risk is driven by how many atherogenic particles are circulating, which genetically \u201chigh-risk\u201d particles are present, and how much inflammation is active in the vessel wall. At the heart of this newer view is a practical triad of biomarkers: apolipoprotein B-100 (ApoB), which counts the number of atherogenic lipoprotein particles;\u00b9 lipoprotein(a) [Lp(a)], a mostly inherited LDL-like particle with added thrombotic risk;\u00b2 and high-sensitivity C-reactive protein (hsCRP), a marker that tracks systemic and vascular inflammation.\u00b3<\/p>\n

LDL-C still matters and remains the standard therapeutic target, but clinical experience (and growing evidence) shows that LDL-C can miss important risk\u2014especially when ApoB is high, Lp(a) is elevated, or hsCRP suggests ongoing inflammation.\u2074 In many patients, these three factors stack together and create risk that feels \u201cout of proportion\u201d to traditional lipid panels. When you compare this biochemical and genetic risk profile with behavioral insults like cigarette smoking, the hierarchy of risk becomes even more nuanced, reinforcing the need for personalized prevention strategies in both primary and secondary prevention.\u2075<\/p>\n

\"\"<\/h3>\n

The Molecular Framework of Apolipoprotein B-100 and Particle Pathogenicity<\/h3>\n

Atherosclerosis doesn\u2019t start because the blood contains \u201ctoo much cholesterol\u201d in the abstract. It starts because too many atherogenic particles are circulating, and a fraction of them get trapped in the artery wall.\u2076 The single best way to understand this is to think in terms of particle number, not just cholesterol mass.\u2076<\/p>\n

Apolipoprotein B (ApoB) is the key structural protein on all potentially atherogenic lipoproteins: very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and also lipoprotein(a).\u2078 Each of these particles carries exactly one ApoB-100 molecule, which makes ApoB a convenient biological \u201ccounter\u201d: the ApoB concentration in plasma tells you how many atherogenic particles are present.\u2077<\/p>\n

This is why relying exclusively on LDL-C can be misleading in some common clinical settings\u2014especially hypertriglyceridemia, metabolic syndrome, and type 2 diabetes.\u2076 In these states, LDL particles often carry less cholesterol per particle, shifting toward small, dense LDL (sdLDL). That means a patient can show an \u201cacceptable\u201d LDL-C value while still having a high number of LDL particles\u2014a pattern often described as LDL-C\/ApoB discordance.\u2079 ApoB measurement bypasses that limitation by directly reflecting particle burden, which better captures the likelihood of lipoprotein entry into the arterial intima.\u2077<\/p>\n

Mechanisms of Subendothelial Infiltration and Retention<\/h3>\n

Atherosclerosis begins when the endothelium\u2014normally a smooth barrier\u2014becomes more permeable or dysfunctional, often due to shear stress, oxidative injury, metabolic dysfunction, or chemical exposure (including tobacco smoke).\u00b9\u00b9 Once that barrier is compromised, ApoB-containing particles can move into the arterial intima.\u00b9\u2070<\/p>\n

What matters next is not only entry, but retention. In the subendothelial space, ApoB particles interact with the extracellular matrix rather than simply drifting by concentration gradients.\u00b9\u00b2 ApoB-100 contains positively charged regions that bind to negatively charged sulfate groups on arterial proteoglycans. This electrostatic interaction is one of the reasons particles become \u201cstuck\u201d in the vessel wall\u2014an essential early step in plaque formation.\u00b9\u2070 Once trapped, particles undergo oxidative and enzymatic modification, generating oxidized lipoproteins that are far more inflammatory and immunogenic than native particles.\u00b9\u00b3<\/p>\n

These modified particles act like danger signals. They recruit monocytes, promote macrophage uptake through scavenger receptors, and drive the formation of lipid-laden foam cells\u2014one of the earliest histologic hallmarks of atherosclerotic lesions.\u00b9\u00b3<\/p>\n

Stoichiometry and Diagnostic Precision of ApoB<\/h3>\n

ApoB\u2019s clinical advantage is not only conceptual\u2014it\u2019s practical. Much of routine LDL-C reporting still depends on calculated methods, most commonly the Friedewald equation:\u00b9\u2074<\/p>\n

This approach becomes less accurate when triglycerides are elevated (typically when TG exceed ~3.5\u20134 mmol\/L) or when blood is drawn in a non-fasting state.\u00b9\u2074 ApoB, in contrast, is measured directly through immunoassays (immunoturbidimetric or immunonephelometric methods) that have been internationally standardized.\u00b9\u2075 In practice, ApoB tends to show lower analytic bias and better reproducibility than calculated lipid measures, which is why it is increasingly favored for assessing particle-driven risk.\u2077<\/p>\n\n\n\n\n\n\n\n\n
Physiological Metric<\/strong><\/td>\nDiagnostic Method<\/strong><\/td>\nSensitivity to Fasting<\/strong><\/td>\n<\/tr>\n<\/thead>\n
LDL-C<\/td>\nCholesterol mass<\/td>\nCalculation (Friedewald)<\/td>\n<\/tr>\n
ApoB-100<\/td>\nParticle count (1:1 ratio)<\/td>\nDirect measurement<\/td>\n<\/tr>\n
Non-HDL-C<\/td>\nAll atherogenic cholesterol<\/td>\nCalculation (TC \u2212 HDL-C)<\/td>\n<\/tr>\n
Lp(a)<\/td>\nGenetic particle subtype<\/td>\nImmunoturbidimetric<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Lipoprotein(a): The Genetic Vanguard of Atherothrombosis<\/h3>\n

Lp(a) is one of the most clinically important (and frustrating) lipoproteins because it is largely genetically determined and minimally affected by lifestyle changes. Structurally, Lp(a) looks like an LDL particle with an attached additional protein\u2014apolipoprotein(a) [apo(a)]\u2014linked to ApoB-100 by a disulfide bond.\u00b2 It\u2019s this additional apo(a) component that makes Lp(a) biologically distinctive and often more dangerous than standard LDL. Some estimates suggest it may be several-fold more potent as a driver of cardiovascular disease than LDL alone.\u00b9\u2076<\/p>\n

\"\"<\/h3>\n

Genetic Regulation and Kringle IV Complexity<\/h3>\n

Lp(a) levels are mainly controlled by the LPA gene on chromosome 6q26\u2013q27. Lp(a) concentration is typically 70% to 90% heritable and remains relatively stable over a lifetime, unlike LDL-C which can shift substantially with diet, weight loss, and medications.\u00b9\u2077 The striking variability in Lp(a) between individuals\u2014sometimes over a 1000-fold range\u2014comes largely from copy-number variation in the Kringle IV type 2 (KIV2) repeats within apo(a).\u00b9\u2078<\/p>\n

Kringle domains are looped structures stabilized by disulfide bonds. Apo(a) contains multiple kringle subtypes (KIV1\u2013KIV10), but KIV2 is the one that varies widely across people. Those with fewer KIV2 repeats generally make smaller apo(a) isoforms and tend to have higher plasma Lp(a) levels. This inverse relationship between apo(a) size and Lp(a) concentration explains much of the genetic contribution to cardiovascular risk from Lp(a).\u00b9\u2079<\/p>\n

The Dual Mechanisms of Lp(a) Pathogenicity<\/h3>\n

Lp(a) increases risk through two main pathways that overlap in real-world disease: a pro-atherogenic\/pro-inflammatory pathway and a pro-thrombotic\/anti-fibrinolytic pathway.\u00b2\u00b2<\/p>\n

Atherogenic and pro-inflammatory drive:<\/strong> Like other ApoB particles, Lp(a) can cross the endothelium and accumulate in the intima. But Lp(a) is also a major carrier of oxidized phospholipids (OxPL) in plasma.\u00b2\u2070 OxPL behave like strong inflammatory ligands, promoting endothelial activation, smooth muscle proliferation, macrophage dysfunction, and sometimes apoptosis\u2014features that contribute to plaque growth and instability.\u00b2\u2070<\/p>\n

Thrombotic and anti-fibrinolytic interference:<\/strong> Apo(a) shares significant structural homology with plasminogen.\u00b2\u00b9 Because of this resemblance, Lp(a) can compete with plasminogen for binding sites on fibrin, interfering with plasmin generation and impairing fibrinolysis.\u00b2\u00b2 In effect, Lp(a) encourages thrombus persistence, increasing the chance that plaque rupture leads to a clinically significant occlusive event such as myocardial infarction.\u00b2\u00b2<\/p>\n

Systemic Inflammation and the Sentinel Role of hsCRP<\/h3>\n

Atherosclerosis is now widely understood as a chronic inflammatory condition affecting the arterial wall.\u00b2\u00b3 Among the inflammatory biomarkers available clinically, hsCRP remains the most commonly used and best standardized.\u00b3 hsCRP does not tell you where inflammation is coming from, but persistent low-grade elevation strongly correlates with vascular inflammatory risk.\u00b3<\/p>\n

The NLRP3 Inflammasome and CRP Induction<\/h3>\n

When cholesterol crystals and oxidized ApoB particles build up in the intima, they activate immune pathways, including the NLRP3 inflammasome in macrophages.\u00b2\u2074 This leads to processing of pro-interleukin-1\u03b2 and pro-IL-18 into active cytokines.\u00b2\u2074 These cytokines stimulate downstream IL-6 signaling, which triggers the liver to synthesize and release CRP.\u00b2\u2075<\/p>\n

CRP can spike dramatically during infection, but chronically elevated hsCRP (often defined as hsCRP \u2265 2 mg\/L) behaves more like a \u201csmoke detector\u201d for ongoing vascular inflammation and future cardiovascular events.\u00b3<\/p>\n

Lessons from the JUPITER Trial<\/h3>\n

The JUPITER trial was a turning point because it showed that inflammatory risk can identify high-risk patients even when LDL-C looks fine.\u00b2\u2076 The study enrolled individuals with LDL-C below usual treatment thresholds (<130 mg\/dL) but with hsCRP \u22652.0 mg\/L. Participants receiving rosuvastatin 20 mg daily had a 44% reduction in major cardiovascular events.\u00b2\u2076 Clinically, the takeaway was simple: some patients carry substantial risk through inflammation even when they do not appear \u201chyperlipidemic\u201d by LDL-C alone.<\/p>\n

Mapping the Interplay: Synergistic Risk and Pathogenic Cross-talk<\/h3>\n

ApoB, Lp(a), and hsCRP do not operate in isolation. Their relationship is better described as interactive, with overlapping mechanisms that can amplify each other\u2019s harm.\u2074<\/p>\n

High ApoB means more particles enter the vessel wall and more substrate becomes available for oxidative modification. Those modified particles intensify inflammation, raising hsCRP. Inflammation then further disrupts endothelial function, making it easier for additional ApoB particles to enter\u2014creating a self-reinforcing loop.\u00b2\u00b3<\/p>\n

This synergy shows up clearly in large population studies. In a study of over 320,000 UK Biobank participants, LDL-C, Lp(a), and hsCRP were each independently associated with major adverse cardiovascular events (MACE), but the combined effect was far greater than any single marker alone.\u2074<\/p>\n\n\n\n\n\n\n\n\n\n
Biomarker Risk Strata<\/strong><\/td>\nMACE Risk Elevation (Non-users of Statins)<\/strong><\/td>\n<\/tr>\n<\/thead>\n
All Markers Low<\/td>\n1.00 (Reference)<\/td>\n<\/tr>\n
High LDL-C Only<\/td>\n+13% risk per SD<\/td>\n<\/tr>\n
High Lp(a) Only<\/td>\n+8% risk per SD<\/td>\n<\/tr>\n
High hsCRP Only<\/td>\n+6% risk per SD<\/td>\n<\/tr>\n
Triple Elevation<\/td>\n+77% risk (HR 1.77)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparison of Biomarker Risks to the Pathogenic Impact of Smoking<\/h3>\n

Smoking remains one of the most aggressive cardiovascular toxins because it generates oxidative stress, drives chronic inflammation, and directly injures the endothelium.\u00b2\u2077 The question clinicians often ask is: how does smoking compare to lipid and biomarker risk?<\/p>\n

INTERHEART provides one of the most useful comparisons because it included diverse populations across 52 countries.\u2075 It showed that current smoking had one of the highest individual odds ratios for MI, but dyslipidemia (measured by ApoB\/ApoA1 ratio) carried an even larger population attributable risk, because dyslipidemia is so common globally.\u00b2\u2078<\/p>\n\n\n\n\n\n\n\n\n
Risk Factor<\/strong><\/td>\nOdds Ratio (OR) for MI<\/strong><\/td>\nPopulation Attributable Risk (PAR)<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Current Smoking<\/td>\n3.63<\/td>\n35.7% (Global)<\/td>\n<\/tr>\n
High ApoB\/ApoA1 Ratio<\/td>\n3.43<\/td>\n54.1% (Global)<\/td>\n<\/tr>\n
Diabetes Mellitus<\/td>\n3.42<\/td>\n16.4%<\/td>\n<\/tr>\n
Hypertension<\/td>\n1.89<\/td>\n10.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The Female Paradox: Sex-Specific Risk Sensitivities<\/h3>\n

Large cohorts show that women may experience a greater relative increase in MI risk from certain exposures, especially smoking and metabolic dysfunction.\u00b2\u2079 In UK Biobank, current smoking was linked to a hazard ratio for MI of 3.46 in women compared with 2.23 in men, producing a ratio of hazard ratios (RHR) of 1.55.\u00b2\u2079<\/p>\n

Clinical Implications: Managing the Residual Risk Triad<\/h3>\n

Even with excellent statin therapy and strong LDL-C lowering, cardiovascular events still occur. This is often referred to as residual risk, and it commonly reflects a combination of residual particle risk (ApoB), genetic risk (Lp(a)), and residual inflammatory risk (hsCRP).\u00b3\u2070<\/p>\n

Statins lower LDL-C and reduce events, but they have little effect on Lp(a), and multiple studies suggest statins may increase Lp(a) modestly (often ~10\u201320%).\u00b3\u00b9 PCSK9 inhibitors reduce LDL-C substantially and also lower Lp(a) by about ~27%.\u00b3\u00b2<\/p>\n

The most promising future approach is direct Lp(a) lowering using antisense oligonucleotides (ASOs) or siRNA platforms, which have shown 80\u201390% reductions in early studies.\u00b3\u00b3 Finally, inflammation-focused trials such as CANTOS demonstrated that reducing inflammatory signaling (independent of lipids) can reduce MACE, reinforcing the clinical reality that inflammation is not just a bystander.\u00b3\u2074<\/p>\n

Conclusion: The Integrated Risk Map<\/h3>\n

Preventive cardiology is increasingly moving from a single-marker \u201ccholesterol hypothesis\u201d toward a more integrated approach. In practical terms, ApoB tells you particle burden, Lp(a) tells you inherited atherothrombotic risk, and hsCRP tells you about inflammatory activation. When these risks cluster, events can occur despite \u201cgood\u201d LDL-C numbers.<\/p>\n

Used together, these markers support more individualized decisions about therapy intensity and emerging targeted treatments\u2014aimed at achieving the deepest possible reduction in cardiovascular risk.<\/p>\n

References<\/h3>\n
    \n
  1. Nicholls SJ, Nelson AJ. Current perspectives on Lp(a)-lowering therapies: Who may benefit?.\u00a0Kardiol Pol<\/i>. 2025;83(6):688-694. doi:10.33963\/v.phj.106327<\/li>\n
  2. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.\u00a0J Am Coll Cardiol<\/i>. 2017;69(6):692-711. doi:10.1016\/j.jacc.2016.11.042<\/li>\n
  3. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.\u00a0Circulation<\/i>. 2001;103(13):1813-1818. doi:10.1161\/01.cir.103.13.1813<\/li>\n
  4. Markus MRP, Ittermann T, Mari\u00f1o Coronado J, et al. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.\u00a0Eur Heart J<\/i>. 2025;46(39):3863-3874. doi:10.1093\/eurheartj\/ehaf281<\/li>\n
  5. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.\u00a0Lancet<\/i>. 2004;364(9438):937-952. doi:10.1016\/S0140-6736(04)17018-9<\/li>\n
  6. Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is Over.\u00a0JAMA Cardiol<\/i>. 2022;7(3):257-258. doi:10.1001\/jamacardio.2021.5080<\/li>\n
  7. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.\u00a0Clin Chem<\/i>. 2009;55(3):407-419. doi:10.1373\/clinchem.2008.118356<\/li>\n
  8. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.\u00a0Can J Cardiol<\/i>. 2021;37(8):1129-1150. doi:10.1016\/j.cjca.2021.03.016<\/li>\n
  9. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number.\u00a0J Clin Lipidol<\/i>. 2011;5(2):105-113. doi:10.1016\/j.jacl.2011.02.001<\/li>\n
  10. Tabas I, Williams KJ, Bor\u00e9n J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.\u00a0Circulation<\/i>. 2007;116(16):1832-1844. doi:10.1161\/CIRCULATIONAHA.106.676890<\/li>\n
  11. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis.\u00a0Arterioscler Thromb Vasc Biol<\/i>. 2014;34(3):509-515. doi:10.1161\/ATVBAHA.113.300156<\/li>\n
  12. Bor\u00e9n J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity.\u00a0Curr Opin Lipidol<\/i>. 2016;27(5):473-483. doi:10.1097\/MOL.0000000000000330<\/li>\n
  13. Miller YI, Choi SH, Wiesner P, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity.\u00a0Circ Res<\/i>. 2011;108(2):235-248. doi:10.1161\/CIRCRESAHA.110.223875<\/li>\n
  14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.\u00a0Clin Chem<\/i>. 1972;18(6):499-502.<\/li>\n
  15. Albers JJ, Marcovina SM. Standardization of apolipoprotein B and A-I measurements.\u00a0Clin Chem<\/i>. 1989;35(7):1357-1361.<\/li>\n
  16. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study.\u00a0Circulation<\/i>. 2008;117(2):176-184. doi:10.1161\/CIRCULATIONAHA.107.715698<\/li>\n
  17. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.\u00a0J Clin Invest<\/i>. 1992;90(1):52-60. doi:10.1172\/JCI115855<\/li>\n
  18. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups.\u00a0Hum Genet<\/i>. 1991;86(6):607-614. doi:10.1007\/BF00201550<\/li>\n
  19. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity.\u00a0Curr Opin Lipidol<\/i>. 2004;15(2):167-174. doi:10.1097\/00041433-200404000-00009<\/li>\n
  20. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma.\u00a0J Lipid Res<\/i>. 2008;49(10):2230-2239. doi:10.1194\/jlr.M800174-JLR200<\/li>\n
  21. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.\u00a0Nature<\/i>. 1987;330(6144):132-137. doi:10.1038\/330132a0<\/li>\n
  22. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models.\u00a0Clin Biochem<\/i>. 2004;37(5):333-343. doi:10.1016\/j.clinbiochem.2003.12.007<\/li>\n
  23. Libby P. Inflammation in atherosclerosis.\u00a0Nature<\/i>. 2002;420(6917):868-874. doi:10.1038\/nature01323<\/li>\n
  24. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.\u00a0Nature<\/i>. 2010;464(7293):1357-1361. doi:10.1038\/nature08938<\/li>\n
  25. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.\u00a0Circ Res<\/i>. 2016;118(1):145-156. doi:10.1161\/CIRCRESAHA.115.306656<\/li>\n
  26. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.\u00a0N Engl J Med<\/i>. 2008;359(21):2195-2207. doi:10.1056\/NEJMoa0807646<\/li>\n
  27. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update.\u00a0J Am Coll Cardiol<\/i>. 2004;43(10):1731-1737. doi:10.1016\/j.jacc.2003.12.047<\/li>\n
  28. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study.\u00a0Lancet<\/i>. 2008;372(9634):224-233. doi:10.1016\/S0140-6736(08)61076-4<\/li>\n
  29. Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants.\u00a0BMJ<\/i>. 2018;363:k4247. Published 2018 Nov 7. doi:10.1136\/bmj.k4247<\/li>\n
  30. Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin.\u00a0Eur Heart J<\/i>. 2016;37(22):1720-1722. doi:10.1093\/eurheartj\/ehw024<\/li>\n
  31. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels.\u00a0Eur Heart J<\/i>. 2020;41(24):2275-2284. doi:10.1093\/eurheartj\/ehz310<\/li>\n
  32. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.\u00a0N Engl J Med<\/i>. 2017;376(18):1713-1722. doi:10.1056\/NEJMoa1615664<\/li>\n
  33. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.\u00a0N Engl J Med<\/i>. 2020;382(3):244-255. doi:10.1056\/NEJMoa1905239<\/li>\n
  34. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.\u00a0N Engl J Med<\/i>. 2017;377(12):1119-1131. doi:10.1056\/NEJMoa1707914<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Stel je een man voor die Sam heet. Sam is het type persoon dat we allemaal willen zijn. Hij ren elke ochtend vijf mijl, hij eet volop kleurrijke groenten en hij vermijdt junkfood. Toen Sam naar zijn jaarlijkse controle ging, had zijn arts geweldig nieuws. De arts keek naar Sams bloedtest en zei: \u201cJe waarden zijn perfect! Je totale cholesterol is laag en je LDL ziet er geweldig uit. Je hart is in opperbeste conditie.\u201d<\/p>","protected":false},"author":16,"featured_media":8469,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[252,219,223,224],"tags":[],"class_list":["post-8457","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-inflammation-markers","category-lipids-medications-and-testing","category-plaque-arteries-and-disease","category-regression-and-reversal"],"acf":[],"yoast_head":"\nIntegrative Dynamics of Apolipoprotein B, Lipoprotein(a), and C-Reactive Protein in Atherosclerotic Progression - The Premiere Heart Health Education Platform<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curingheartdisease.com\/nl\/integratieve-dynamica-van-apolipoproteine-b-lipoproteine-en-c-reactief-proteine-bij-atherosclerotische-progressie\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Integrative Dynamics of Apolipoprotein B, Lipoprotein(a), and C-Reactive Protein in Atherosclerotic Progression - The Premiere Heart Health Education Platform\" \/>\n<meta property=\"og:description\" content=\"Imagine a man named Sam. Sam is the kind of person we all want to be. He runs five miles every morning, he eats plenty of colorful vegetables, and he avoids junk food. When Sam went to his yearly check-up, his doctor had great news. The doctor looked at Sam\u2019s blood test and said, "Your numbers are perfect! Your total cholesterol is low, and your LDL looks great. Your heart is in tip-top shape."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curingheartdisease.com\/nl\/integratieve-dynamica-van-apolipoproteine-b-lipoproteine-en-c-reactief-proteine-bij-atherosclerotische-progressie\/\" \/>\n<meta property=\"og:site_name\" content=\"The Premiere Heart Health Education Platform\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/curingheartdisease\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-12T14:56:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T14:59:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-19.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Peter Megdal PhD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:site\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"Peter Megdal PhD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/\"},\"author\":{\"name\":\"Peter Megdal PhD\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\"},\"headline\":\"Integrative Dynamics of Apolipoprotein B, Lipoprotein(a), and C-Reactive Protein in Atherosclerotic Progression\",\"datePublished\":\"2025-12-12T14:56:24+00:00\",\"dateModified\":\"2026-07-16T14:59:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/\"},\"wordCount\":2737,\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/post-image-19.jpg\",\"articleSection\":[\"Inflammation Markers\",\"Lipids, Medications and Testing\",\"Plaque, Arteries and Disease\",\"Regression and Reversal\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/\",\"name\":\"Integrative Dynamics of Apolipoprotein B, Lipoprotein(a), and C-Reactive Protein in Atherosclerotic Progression - The Premiere Heart Health Education Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/post-image-19.jpg\",\"datePublished\":\"2025-12-12T14:56:24+00:00\",\"dateModified\":\"2026-07-16T14:59:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/post-image-19.jpg\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/post-image-19.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Integrative Dynamics of Apolipoprotein B, Lipoprotein(a), and C-Reactive Protein in Atherosclerotic Progression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"name\":\"The Premiere Heart Health Education Platform\",\"description\":\"To make available to the public the state of the art information on how to reverse heart disease. This is an evidence-based organization utilizing the best available science, including diet, exercise drugs, and other resources to best fight this disease.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curingheartdisease.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\",\"name\":\"Curing Heart Disease, LLC\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"width\":512,\"height\":512,\"caption\":\"Curing Heart Disease, LLC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/curingheartdisease\",\"https:\\\/\\\/x.com\\\/RMHDInc\",\"https:\\\/\\\/www.instagram.com\\\/rmhdinc\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm8dh9c_D5RfJL7Z1f-yY4w\"],\"description\":\"Curing Heart Disease, LLC is an independent cardiovascular health education organization that publishes evidence-based articles, videos, podcasts, and educational tools about cardiovascular disease prevention, lipid science, nutrition, exercise, and related health topics.\",\"founder\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"foundingPerson\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"knowsAbout\":[\"Cardiovascular health\",\"Cardiovascular disease prevention\",\"Heart disease education\",\"Nutrition\",\"Exercise\",\"Lipid science\",\"Atherosclerosis\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\",\"givenName\":\"Peter\",\"familyName\":\"Megdal\",\"honorificSuffix\":\"PhD\",\"jobTitle\":\"Nutrition Researcher and Cardiovascular Health Educator\",\"description\":\"Peter Megdal, PhD, is a nutrition researcher, cardiovascular health educator, published researcher, and longtime competitive cyclist. He earned a PhD in nutrition from the University of Massachusetts and publishes evidence-based cardiovascular health education through Curing Heart Disease.\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\"},\"worksFor\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"affiliation\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"alumniOf\":{\"@type\":\"CollegeOrUniversity\",\"name\":\"University of Massachusetts\"},\"knowsAbout\":[\"Nutrition\",\"Cardiovascular health education\",\"Cardiovascular disease prevention\",\"Lipid science\",\"Exercise physiology\",\"Scientific research\"],\"sameAs\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/author\\\/peter-megdal\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/peter-megdal-56075a2\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Integratieve dynamiek van apolipoprote\u00efne B, lipoprote\u00efne(a) en C-reactieve prote\u00efne bij atherosclerotische progressie - Het Premiere Hartgezondheid Educatieplatform","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curingheartdisease.com\/nl\/integratieve-dynamica-van-apolipoproteine-b-lipoproteine-en-c-reactief-proteine-bij-atherosclerotische-progressie\/","og_locale":"nl_NL","og_type":"article","og_title":"Integrative Dynamics of Apolipoprotein B, Lipoprotein(a), and C-Reactive Protein in Atherosclerotic Progression - The Premiere Heart Health Education Platform","og_description":"Imagine a man named Sam. Sam is the kind of person we all want to be. He runs five miles every morning, he eats plenty of colorful vegetables, and he avoids junk food. When Sam went to his yearly check-up, his doctor had great news. The doctor looked at Sam\u2019s blood test and said, \"Your numbers are perfect! Your total cholesterol is low, and your LDL looks great. Your heart is in tip-top shape.\"","og_url":"https:\/\/www.curingheartdisease.com\/nl\/integratieve-dynamica-van-apolipoproteine-b-lipoproteine-en-c-reactief-proteine-bij-atherosclerotische-progressie\/","og_site_name":"The Premiere Heart Health Education Platform","article_publisher":"https:\/\/www.facebook.com\/curingheartdisease","article_published_time":"2025-12-12T14:56:24+00:00","article_modified_time":"2026-07-16T14:59:52+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-19.jpg","type":"image\/jpeg"}],"author":"Peter Megdal PhD","twitter_card":"summary_large_image","twitter_creator":"@RMHDInc","twitter_site":"@RMHDInc","twitter_misc":{"Geschreven door":"Peter Megdal PhD","Geschatte leestijd":"13 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/#article","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/"},"author":{"name":"Peter Megdal PhD","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53"},"headline":"Integrative Dynamics of Apolipoprotein B, Lipoprotein(a), and C-Reactive Protein in Atherosclerotic Progression","datePublished":"2025-12-12T14:56:24+00:00","dateModified":"2026-07-16T14:59:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/"},"wordCount":2737,"publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-19.jpg","articleSection":["Inflammation Markers","Lipids, Medications and Testing","Plaque, Arteries and Disease","Regression and Reversal"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/","url":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/","name":"Integratieve dynamiek van apolipoprote\u00efne B, lipoprote\u00efne(a) en C-reactieve prote\u00efne bij atherosclerotische progressie - Het Premiere Hartgezondheid Educatieplatform","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/#primaryimage"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-19.jpg","datePublished":"2025-12-12T14:56:24+00:00","dateModified":"2026-07-16T14:59:52+00:00","breadcrumb":{"@id":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/#primaryimage","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-19.jpg","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2025\/12\/post-image-19.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.curingheartdisease.com\/integrative-dynamics-of-apolipoprotein-b-lipoproteina-and-c-reactive-protein-in-atherosclerotic-progression\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curingheartdisease.com\/"},{"@type":"ListItem","position":2,"name":"Integrative Dynamics of Apolipoprotein B, Lipoprotein(a), and C-Reactive Protein in Atherosclerotic Progression"}]},{"@type":"WebSite","@id":"https:\/\/www.curingheartdisease.com\/#website","url":"https:\/\/www.curingheartdisease.com\/","name":"Het vooraanstaande educatieve platform voor hartgezondheid","description":"Het ter beschikking stellen aan het publiek van de meest geavanceerde informatie over het omkeren van hartaandoeningen. Dit is een op bewijs gebaseerde organisatie die gebruikmaakt van de best beschikbare wetenschap, waaronder voeding, beweging, medicijnen en andere middelen om deze ziekte zo goed mogelijk te bestrijden.","publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curingheartdisease.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.curingheartdisease.com\/#organization","name":"Curing Heart Disease, LLC","url":"https:\/\/www.curingheartdisease.com\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","width":512,"height":512,"caption":"Curing Heart Disease, LLC"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/curingheartdisease","https:\/\/x.com\/RMHDInc","https:\/\/www.instagram.com\/rmhdinc\/","https:\/\/www.youtube.com\/channel\/UCm8dh9c_D5RfJL7Z1f-yY4w"],"description":"Curing Heart Disease, LLC is een onafhankelijke organisatie voor voorlichting over cardiovasculaire gezondheid die op bewijs gebaseerde artikelen, video's, podcasts en educatieve hulpmiddelen publiceert over de preventie van hart- en vaatziekten, lipidenwetenschap, voeding, lichaamsbeweging en gerelateerde gezondheidsonderwerpen.","founder":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"foundingPerson":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"knowsAbout":["Cardiovascular health","Cardiovascular disease prevention","Heart disease education","Nutrition","Exercise","Lipid science","Atherosclerosis"]},{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD","url":"https:\/\/www.curingheartdisease.com\/peters-story\/","givenName":"Peter","familyName":"Megdal","honorificSuffix":"PhD","jobTitle":"Nutrition Researcher and Cardiovascular Health Educator","description":"Peter Megdal, PhD is voedingsonderzoeker, voorlichter op het gebied van hart- en vaatgezondheid, gepubliceerd onderzoeker en al jarenlang wedstrijdfietser. Hij behaalde een doctoraat in de voedingswetenschappen aan de Universiteit van Massachusetts en publiceert via Curing Heart Disease wetenschappelijk onderbouwde voorlichting over hart- en vaatgezondheid.","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/peters-story\/"},"worksFor":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"affiliation":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"alumniOf":{"@type":"CollegeOrUniversity","name":"University of Massachusetts"},"knowsAbout":["Nutrition","Cardiovascular health education","Cardiovascular disease prevention","Lipid science","Exercise physiology","Scientific research"],"sameAs":["https:\/\/www.curingheartdisease.com\/author\/peter-megdal\/","https:\/\/www.linkedin.com\/in\/peter-megdal-56075a2\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/posts\/8457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/comments?post=8457"}],"version-history":[{"count":19,"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/posts\/8457\/revisions"}],"predecessor-version":[{"id":12117,"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/posts\/8457\/revisions\/12117"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/media\/8469"}],"wp:attachment":[{"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/media?parent=8457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/categories?post=8457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/nl\/wp-json\/wp\/v2\/tags?post=8457"}],"curies":[{"name":"goed gespeeld","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}